| 1. |
Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JYESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:iv35-8.
|
| 2. |
Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo
KN, Maki RG, et al. NCCN Task Force report: update on the management of
patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw 2010;8
Suppl 2:S1-41
|
| 3. |
Kawanowa K, sakumai Y, Sakura S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37:1527-35
|
| 4. |
Fletcher CDM, Berman J, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
|
| 5. |
Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31:113-20
|
| 6. |
Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83
|
| 7. |
Polkowski M, Butruk E. Submucosal lesions. Gastrointest Endosc Clin N Am 2005;15:33-55
|
| 8. |
Le Cesne A, Landi B, Bonvalot S et al. Recommandations pour la prise en charge des tumeurs stromales gastro-intestinales. Hépato-Gastro 2005 ; 5 : 377-9.
|
| 9. |
Plaat BE, Hollema H., Molenaar W.M., et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-20.
|
| 10. |
Changchien CR, Wu MC, Tasi WS, et al. Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining.Dis Colon Rectum 2004 ;49:1922-29
|
| 11. |
Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al.Efficacy and safety of imatinib in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
|
| 12. |
Verweij J, Casali PG, J Zalcberg J, Le Cesne A, Reichard P, Blay JY, et al.Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.. Lancet 2004;364:1127-34.
|
| 13. |
Blanke CD, Demetri GD, Van Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-25
|
| 14. |
Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32
|
| 15. |
Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int 2006;56:1-9
|
| 16. |
Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30:477-89.
|
| 17. |
Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
|
| 18. |
Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer 2005;103:821-9.
|
| 19. |
Emile JF, Brahim S, Coindre J, Monges G, Scoazec JY, Blay JY, et al. Molecular epidemiology of GISTs: Incidence of PDGFRA and KIT exon 9 mutations in the large French population-based study molecGIST. J Clin Oncol 2009; 27: 15s (abstract 10535)
|
| 20. |
Blay JY, Reichardt P. Advanced gastrointestinal stromal tumor in Europe:
a review of updated treatment recommendations. Expert Rev Anticancer Ther
2009 ;9:831-8
|
| 21. |
Hohenberger P, Eisenberg B. Role of Surgery Combined with Kinase Inhibition in the Management of Gastrointestinal Stromal Tumor (GIST). Ann Surg Oncol 2010 Apr 21. [Epub ahead of print]
|
| 22. |
Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A, Bonvalot S. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004;30:1098-103
|
| 23. |
Bonvalot S, Eldweny H, Le Pechoux C, Vanel D, Terrier P, Cavalcanti A, Robert C, Lassau N, Le Cesne A. Impact of Surgery on Advanced Gastrointestinal Stromal Tumors (GIST) in the Imatinib Era. Ann Surg Oncol 2006 Sep 7 [Epub ahead of print]
|
| 24. |
Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis
of 1,452 patients and development of a prognostic model. Ann Surg 2006;244:524-35.
|
| 25. |
Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005;117:316-25
|
| 26. |
Rutkowski P, Nowecki Z, Dziewirski W, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93:304-11
|
| 27. |
Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-31.
|
| 28. |
Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
|
| 29. |
Zalcberg JR, Verweij J, Casali PG, J, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005 ;41:1751-7
|
| 30. |
Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients . J Clin Oncol 2007 25: 10004 (abstract)
|
| 31. |
Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009;27:3141-7
|
| 32. |
Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104
|
| 33. |
Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-38
|
| 34. |
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-9
|
| 35. |
Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol 2009 Aug 12. [Epub ahead of print]
|
| 36. |
George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, et al.. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68
|
| 37. |
Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009;45:2293-7.
|
|